|
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1996) Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 156:1714-21
|
|
Duke-Cohan, J S; Morimoto, C; Rocker, J A et al. (1995) A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 270:14107-14
|
|
Martin-Reay, D G; Kamentsky, L A; Weinberg, D S et al. (1994) Evaluation of a new slide-based laser scanning cytometer for DNA analysis of tumors. Comparison with flow cytometry and image analysis. Am J Clin Pathol 102:432-8
|
|
Dawson, A E; Cibas, E S; Bacus, J W et al. (1993) Chromatin texture measurement by Markovian analysis. Use of nuclear models to define and select texture features. Anal Quant Cytol Histol 15:227-35
|
|
Araten, D J; Lawton, T; Ferrara, J et al. (1993) In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation 55:76-82
|
|
Sayegh, M H; Khoury, S J; Hancock, W W et al. (1993) Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc 25:357-8
|
|
Weinberg, D S; Weidner, N (1993) Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117:1132-7
|
|
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 82:2224-34
|
|
Duke-Cohan, J S; Morimoto, C; Schlossman, S F (1993) Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation 56:1188-96
|
|
Hancock, W W; Sayegh, M H; Kwok, C A et al. (1993) Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 55:1112-8
|
Showing the most recent 10 out of 30 publications
